» Articles » PMID: 35819593

Radiosensitizing Effect of Dendrosomal Nanoformulation of Curcumin on Cancer Cells

Overview
Journal Pharmacol Rep
Specialty Pharmacology
Date 2022 Jul 12
PMID 35819593
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Curcumin was found to possess numerous pharmacological activities in clinical research, however, its biological effects together with radiation are yet to be addressed. The present study investigated whether the combined treatment of dendrosomal nanoformulation of curcumin (DNC) and gamma radiation can enhance the radiosensitivity of U87MG and MDA-MB-231 cell lines.

Methods: U87MG and MDA-MB-231 cell lines were exposed to 2 Gray (Gy) and 10 μM DNC determined by MTT assay, then subjected to clonogenic assay, cell cycle assay, and flow cytometric apoptosis analysis. Acridine Orange/Ethidium Bromide (AO/EB) and 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) stained cells were used to study morphologic changes. The expression evaluation of putative cell cycle genes, i.e., P53, P21, CCND1, and CCNB1 was carried out by RT-qPCR.

Results: Our findings indicated that the combined treatment with DNC and radiation might cooperatively augment the efficacy of ionizing radiation in the cancer cells and notably decrease the survival and viability of the cells in a time- and concentration-dependent manner. In addition to a synergistic effect deducted by sensitizer enhancement ratio (SER) assessment, co-treatment resulted in greater apoptotic cells than the individual treatments. Further experiments then indicated that DNC could effectively induce G2/M phase cell cycle arrest and apoptosis following irradiation. Conformably, there was a decrement of CCND1 and CCNB1 expression, and an increment of P53, P21 expression.

Conclusions: The data implied that DNC as a radiosensitizer can enhance the lethal effect of ionizing radiation on cancer cells which could be a promising adjuvant therapy in clinical treatments.

Citing Articles

Compound Taxus exerts marked anti-tumor activity and radiosensitization effect on hepatocellular carcinoma cells.

Gao H, Bu X, Jiang W, Wan Y, Song W Heliyon. 2024; 10(5):e27345.

PMID: 38495161 PMC: 10940940. DOI: 10.1016/j.heliyon.2024.e27345.

References
1.
Brown P, Ahluwalia M, Khan O, Asher A, Wefel J, Gondi V . Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?. J Clin Oncol. 2017; 36(5):483-491. PMC: 6075843. DOI: 10.1200/JCO.2017.75.9589. View

2.
Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M . Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019; 121(12):991-1000. PMC: 6964671. DOI: 10.1038/s41416-019-0619-y. View

3.
Korja M, Raj R, Seppa K, Luostarinen T, Malila N, Seppala M . Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol. 2018; 21(3):370-379. PMC: 6380416. DOI: 10.1093/neuonc/noy164. View

4.
Pearl L, Schierz A, Ward S, Al-Lazikani B, Pearl F . Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015; 15(3):166-80. DOI: 10.1038/nrc3891. View

5.
Pilie P, Tang C, Mills G, Yap T . State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2018; 16(2):81-104. PMC: 8327299. DOI: 10.1038/s41571-018-0114-z. View